Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 2,631 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,631 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $271,782.30. Following the completion of the sale, the chief operating officer directly owned 20,655 shares of the company’s stock, valued at approximately $2,133,661.50. The trade was a 11.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Monday, January 26th, Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17.
• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $222,312.06.

Mirum Pharmaceuticals Stock Performance

MIRM stock traded up $1.65 during trading hours on Tuesday, reaching $105.45. The stock had a trading volume of 670,739 shares, compared to its average volume of 775,404. The stock has a 50-day simple moving average of $81.60 and a 200 day simple moving average of $73.33. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $105.64. The stock has a market capitalization of $5.42 billion, a PE ratio of -122.61 and a beta of 0.49. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. During the same period in the previous year, the business earned ($0.30) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 47.1% compared to the same quarter last year. Analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MIRM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Citizens Jmp lifted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, December 19th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Finally, Evercore ISI restated an “outperform” rating and set a $101.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $107.25.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MIRM. MCF Advisors LLC boosted its holdings in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the period. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $33,000. Comerica Bank boosted its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. Quarry LP acquired a new stake in Mirum Pharmaceuticals during the third quarter worth approximately $41,000. Finally, CWM LLC increased its stake in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.